Evidence map›Paper›PMID 35821355›Full record

ReviewInfectious diseases and therapy2022

Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China.

Yuanyuan Song, Yuchang Li, Hanchao Cheng, Xinyu Du, Jiarun Mi, Linh-Vi Le, Zhongdan Chen, Polin Chan, Jing Sun

Open access · goldAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. [Analysis of epidemiological characteristics and spatial clustering of hepatitis C virus in China from 2018 to 2022].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. [Analysis of the results of the Fuxing Program Action for micro-elimination of hepatitis C in Zhuhai].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Global Epidemiology of Hepatocellular Carcinoma.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Yuanyuan Song *School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongdansantiao, Dongcheng District, Beijing, 100730, People's Republic of China.
Yuchang Li *School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongdansantiao, Dongcheng District, Beijing, 100730, People's Republic of China.
Hanchao ChengSchool of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongdansantiao, Dongcheng District, Beijing, 100730, People's Republic of China.
Xinyu DuSchool of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongdansantiao, Dongcheng District, Beijing, 100730, People's Republic of China.
Jiarun MiSchool of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongdansantiao, Dongcheng District, Beijing, 100730, People's Republic of China.
Linh-Vi LeThe Hepatitis, TB, HIV and Sexually Transmitted Infection Unit, World Health Organization Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines.
Zhongdan ChenThe Hepatitis, TB, HIV and Sexually Transmitted Infection Unit, World Health Organization Representative Office in China, 401 Dongwai Diplomatic Building 23, Dongzhimenwai Dajie, Chaoyang District, Beijing, 100600, People's Republic of China.
Polin ChanThe Hepatitis, TB, HIV and Sexually Transmitted Infection Unit, World Health Organization Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines.
Jing SunSchool of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongdansantiao, Dongcheng District, Beijing, 100730, People's Republic of China. sunjing@sph.pumc.edu.cn.ORCID http://orcid.org/0000-0002-4646-1174
Chinese Academy of Medical Sciences & Peking Union Medical College · CNWorld Health Organization Regional Office for the Western Pacific · PH

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionAs a country that is heavily burdened by hepatitis C, China's successful responses to this public health threat have significant implications for the achievement of the global elimination goal.

methodsThis article reviews China's strategies for prevention, screening, diagnosis, access to direct-acting antiviral agents (DAA) therapy, and patient management of hepatitis C. It also analyses the major challenges and summarizes the valuable successful international experiences that have implications for China to achieve the elimination goal.

resultsTo promote the achievement of elimination, China has taken a series of proactive measures to promote the prevention and treatment of hepatitis C. Compared with other middle-income countries, there is still much room for China to achieve universal screening, diagnosis and treatment based on a streamlined disease management procedure. A stronger role of primary care in an integrated healthcare delivery system and integration of hepatitis C with other infectious disease programs should also be the focus of China's efforts.

conclusionsAs a developing country with a large population, a "micro-elimination" strategy with focused screening and proactive diagnosis and treatment for the vulnerable population may be a more practical approach to eliminating hepatitis C in China. Continued efforts are needed to fully overcome the intellectual property barriers of sofosbuvir for forming the more competitive pan-genotype DAA combinations based on the locally developed DAAs. Meanwhile, the safety net for patients in economic hardship needs to be further strengthened. More importantly, it is necessary to promote patients' willingness and compliance with standard treatment through increased awareness of hepatitis C. The development of an integrated healthcare delivery system, a disease management procedure which is suitable for primary care, and full compliance of the primary care providers are also important to achieve effective cascade care management.

Indexed as

AwarenessDiagnosisDirect-acting antiviral agentsDisease management procedureEliminationHepatitis CIntegrated healthcare delivery systemScreeningTreatment

Identifiers

PMID35821355
PMCPMC9334498
OpenAlexW4285095369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.